Lanean...
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...
Gorde:
| Argitaratua izan da: | J Transplant |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Hindawi Publishing Corporation
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/ https://ncbi.nlm.nih.gov/pubmed/27807479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|